# RedHill Biopharma Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/RedHill Biopharma Ltd.). ## Overview RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases, infectious diseases, and oncology. The company is headquartered in Israel and operates with a U.S.-centered commercial and development focus, while its ordinary shares and ADSs are publicly traded. ## Products & services • Talicia for H. pylori infection • Opaganib (ABC294640) clinical development • RHB-102 (Bekinda) GI and antiemetic programs • RHB-204 Crohn's disease program • RHB-107 (upamostat) antiviral and oncology programs - **Commercial gastrointestinal products** (35%) — Approved and marketed GI therapies, including Talicia for H. pylori infection. - **Clinical-stage oncology programs** (25%) — Investigational cancer-focused assets such as opaganib and RHB-107. - **Clinical-stage gastrointestinal programs** (25%) — Development assets targeting Crohn's disease, IBS-D, nausea, and GI intolerance. - **Partnered development programs** (15%) — Collaborative commercialization and development arrangements outside North America. - Talicia for H. pylori infection - Opaganib (ABC294640) clinical development - RHB-102 (Bekinda) GI and antiemetic programs - RHB-204 Crohn's disease program - RHB-107 (upamostat) antiviral and oncology programs ## Customers RedHill sells primarily into the U.S. pharmaceutical market through physicians, prescribers, and commercial channels that support prescription medicines. Its products are used by patients with gastrointestinal, infectious disease, and oncology-related conditions, while development programs are aimed at future commercialization or partnering with larger biopharma companies. The customer base therefore spans end users, healthcare providers, and licensing/commercial partners depending on product stage. - **Prescribing physicians** (primary) — Doctors in gastroenterology and related specialties who prescribe RedHill's approved or marketed therapies. - **Patients with GI disease** (primary) — Patients treated for H. pylori infection, IBS-D, Crohn's disease, nausea, and other GI conditions. - **Commercial partners** (primary) — Pharmaceutical companies that acquire rights or share commercialization of selected products. - **Clinical investigators** (secondary) — Hospitals, research centers, and investigators involved in company-sponsored trials. - **Healthcare channel intermediaries** (secondary) — Specialty distributors and other commercial channel participants that support product access. - Physicians prescribing GI therapies for H. pylori and related disorders - Patients using prescription treatments for gastrointestinal disease - Healthcare providers and distributors in U.S. commercial channels - Pharma partners licensing or commercializing selected programs - Clinical and research collaborators supporting development assets ## Geography RedHill is based in Israel but its operating model is centered on U.S. development and commercialization, as reflected in its business description and Nasdaq listing. The company also collaborates internationally through product partnerships and ex-North America rights arrangements, including worldwide commercialization outside North America for some assets. Geography matters because clinical development, regulatory approval, and commercial execution are split across the U.S., Israel, and selected partner markets. - Headquartered in Tel-Aviv, Israel - U.S.-focused development and commercialization strategy - Nasdaq-listed with access to U.S. capital markets - International partnering for non-North America rights - Global milestone upside on partnered product sales ## Strategy RedHill's strategy is centered on converting clinical and commercial assets into a larger gastrointestinal franchise while advancing selected development programs in infectious disease and oncology. The Talicia divestment indicates a focus on monetizing existing assets to fund new product opportunities and strengthen the commercial platform. The company is also pursuing partnered development where appropriate to broaden reach without bearing all commercialization burden itself. - **Expand the GI commercial franchise** (short-term) — A broader gastroenterology platform can create repeatable revenue and leverage existing commercial capabilities. - **Advance clinical pipeline assets** (medium-term) — Late-stage programs can create future approved products and diversify revenue beyond one branded therapy. - **Partner and monetize non-core rights** (short-term) — Licensing and divestitures can supply capital while preserving upside through milestones and royalties. - Build a larger GI commercial franchise - Monetize selected assets to fund growth - Advance late-stage clinical programs - Use partnerships for ex-North America reach - Pursue FDA-approved product opportunities ## Risks RedHill faces the usual biotech risks of clinical failure, regulatory delay, and commercialization uncertainty, which are amplified by dependence on a small number of development and product assets. Partnered programs, milestone structures, and product divestitures can also make revenue and cash generation uneven from period to period. Because the company operates across the U.S., Israel, and partner markets, execution risk spans regulatory, legal, and commercial jurisdictions. - **Clinical development failure** [high] — Pipeline value depends on positive trial outcomes for opaganib, RHB-102, RHB-204, and RHB-107. - **Regulatory approval risk** [high] — Late-stage candidates must satisfy FDA and other regulators before commercialization. - **Product concentration** [high] — Commercial performance can depend heavily on a limited number of branded products. - **Partner dependence** [medium] — Milestones and external commercialization outcomes depend on counterparties' execution. - Clinical trial failures could eliminate future product value - Regulatory setbacks could delay or prevent approvals - Commercial concentration increases exposure to key products - Partner milestones are uncertain and timing-sensitive - Cross-border execution adds legal and operational complexity ## Accounting Investors should watch how RedHill accounts for milestone-based consideration, licensing/divestiture proceeds, and partner arrangements, because timing can materially shift reported revenue and cash flow. Clinical-stage biopharma also relies on judgment around research and development costs, asset valuation, and any contingent or deferred consideration tied to commercialization outcomes. If the company carries acquired or developed intangible assets, impairment assessments can be important when programs do not progress as expected. - **Milestone and contingent consideration** — Can create uneven revenue or other income recognition - **R&D expense recognition** — Affects operating results and quarter-to-quarter comparability - **Intangible asset impairment** — Could trigger non-cash write-downs - Milestone-based payments may be recognized over time or upon achievement - Licensing/divestiture gains can create lumpy period-to-period results - R&D expense timing affects reported operating loss and comparability - Intangible asset impairment risk depends on program progress - Contingent consideration valuation can move with sales assumptions --- *Last updated: 2026-09-28T12:13:51.164168+00:00*